A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-11-09
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 16); relationship: not assessed
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 32); relationship: Y
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 100); relationship: not assessed
Data queries
No data queries.